Sartorius Stedim Biotech (CHIX:DIMP) Total Current Assets : €1,621 Mil (As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Sartorius Stedim Biotech Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Sartorius Stedim Biotech's total current assets for the quarter that ended in Sep. 2024 was €1,621 Mil.

Sartorius Stedim Biotech Total Current Assets Historical Data

The historical data trend for Sartorius Stedim Biotech's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Total Current Assets Chart

Sartorius Stedim Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

636.23

873.95

1,455.60

1,671.20

1,415.10

Sartorius Stedim Biotech Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24
Total Current Assets	Get a 7-Day Free Trial															1,618.00	1,525.00	1,415.10	1,697.60	1,620.50

Sartorius Stedim Biotech Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Sartorius Stedim Biotech's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	116.6	+	304.2	+	882.4	+	111.9
	=	1,415

Sartorius Stedim Biotech's Total Current Assets for the quarter that ended in Sep. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	500.8	+	278.1	+	745.7	+	95.9
	=	1,621

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Sartorius Stedim Biotech (CHIX:DIMp) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Sartorius Stedim Biotech's Liquidation Value for the quarter that ended in Sep. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	500.8	-	4058.7	+	0.75 * 278.1	+	0.5 * 745.7
=	-2,976

Sartorius Stedim Biotech Total Current Assets Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius Stedim Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (CHIX:DIMp) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

SRTOY:USA SDMHF:USA 0RG8:UK DIM:France 56S1:Germany DIM:Austria

Address

Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website

https://www.sartorius.com

Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.

Sartorius Stedim Biotech Headlines

No Headlines